{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:34:18Z","timestamp":1790192058589,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10495-025-02136-7","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T05:33:39Z","timestamp":1750916019000},"page":"2238-2253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["DNA damage repair inhibitors boost targeted radionuclide therapy and immunotherapy of prostate cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Bin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"issue":"2024","key":"2136_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics. CA Cancer J Clin 74(2024):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"2136_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG (2021) Prostate cancer. Nat Rev Dis Primers 7:9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0","journal-title":"Nat Rev Dis Primers"},{"key":"2136_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG (2021) Prostate cancer. Lancet 398:1075\u20131090. https:\/\/doi.org\/10.1016\/S0140-6736(21)00950-8","journal-title":"Lancet"},{"key":"2136_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68:325\u2013334. https:\/\/doi.org\/10.1016\/j.eururo.2014.07.020","journal-title":"Eur Urol"},{"key":"2136_CR5","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song X-L, Li X-A, Chen M, Guo J, Yang D-H, Chen Z, Zhao S-C (2023) Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat 68:100962. https:\/\/doi.org\/10.1016\/j.drup.2023.100962","journal-title":"Drug Resist Updat"},{"key":"2136_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, Bono Jd, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"2136_CR7","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenb\u00f6ck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J (2021) Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 7:1635\u20131642. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771","journal-title":"JAMA Oncol"},{"key":"2136_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3322\/caac.21768","volume":"73","author":"EO Aboagye","year":"2023","unstructured":"Aboagye EO, Barwick TD, Haberkorn U (2023) Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin 73:255\u2013274. https:\/\/doi.org\/10.3322\/caac.21768","journal-title":"CA Cancer J Clin"},{"key":"2136_CR9","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/s41587-024-02295-z","volume":"42","author":"M Senior","year":"2024","unstructured":"Senior M (2024) Precision radiation opens a new window on cancer therapy. Nat Biotechnol 42:1003\u20131008. https:\/\/doi.org\/10.1038\/s41587-024-02295-z","journal-title":"Nat Biotechnol"},{"key":"2136_CR10","doi-asserted-by":"publisher","first-page":"114538","DOI":"10.1016\/j.addr.2022.114538","volume":"190","author":"J Sun","year":"2022","unstructured":"Sun J, Huangfu Z, Yang J, Wang G, Hu K, Gao M, Zhong Z (2022) Imaging-guided targeted radionuclide tumor therapy: from concept to clinical translation. Adv Drug Deliv Rev 190:114538. https:\/\/doi.org\/10.1016\/j.addr.2022.114538","journal-title":"Adv Drug Deliv Rev"},{"key":"2136_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.2967\/jnumed.120.250738","volume":"62","author":"H-T Kuo","year":"2021","unstructured":"Kuo H-T, Lin K-S, Zhang Z, Uribe CF, Merkens H, Zhang C, B\u00e9nard F (2021) 177Lu-labeled albumin-binder\u2013conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio. J Nucl Med 62:521\u2013527. https:\/\/doi.org\/10.2967\/jnumed.120.250738","journal-title":"J Nucl Med"},{"key":"2136_CR12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.121.262533","volume":"63","author":"M Xu","year":"2022","unstructured":"Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z (2022) Albumin binder\u2013conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy. J Nucl Med 63:952\u2013958. https:\/\/doi.org\/10.2967\/jnumed.121.262533","journal-title":"J Nucl Med"},{"key":"2136_CR13","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","volume":"50","author":"X Wen","year":"2023","unstructured":"Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X (2023) Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging 50:2846\u20132860. https:\/\/doi.org\/10.1007\/s00259-023-06229-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2136_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","volume":"630","author":"X-Y Cui","year":"2024","unstructured":"Cui X-Y, Li Z, Kong Z, Liu Y, Meng H, Wen Z, Wang C, Chen J, Xu M, Li Y, Gao J, Zhu W, Hao Z, Huo L, Liu S, Yang Z, Liu Z (2024) Covalent targeted radioligands potentiate radionuclide therapy. Nature 630:206\u2013213. https:\/\/doi.org\/10.1038\/s41586-024-07461-6","journal-title":"Nature"},{"key":"2136_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jconrel.2024.09.040","volume":"375","author":"Z Huangfu","year":"2024","unstructured":"Huangfu Z, Yang J, Sun J, Xu B, Tao L, Wu J, Wang F, Wang G, Meng F, Zhong Z (2024) Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer. J Control Release 375:767\u2013775. https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.040","journal-title":"J Control Release"},{"key":"2136_CR16","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.123.265433","volume":"64","author":"C Meyer","year":"2023","unstructured":"Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M (2023) Tandem isotope therapy with (225)Ac- and (177)Lu-PSMA-617 in a murine model of prostate cancer. J Nucl Med 64:1772\u20131778. https:\/\/doi.org\/10.2967\/jnumed.123.265433","journal-title":"J Nucl Med"},{"key":"2136_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.123.266842","volume":"65","author":"A Moradi Tuchayi","year":"2024","unstructured":"Moradi Tuchayi A, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A, Juarez R, Lawhn-Heath C, Wang Y, de Kouchkovsky I, Hope TA (2024) Real-world experience with (177)Lu-PSMA-617 radioligand therapy after food and drug administration approval. J Nucl Med 65:735\u2013739. https:\/\/doi.org\/10.2967\/jnumed.123.266842","journal-title":"J Nucl Med"},{"key":"2136_CR18","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s00259-024-06677-y","volume":"51","author":"S Satapathy","year":"2024","unstructured":"Satapathy S, Yadav MP, Ballal S, Sahoo RK, Bal C (2024) [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study. Eur J Nucl Med Mol Imaging 51:2495\u20132503. https:\/\/doi.org\/10.1007\/s00259-024-06677-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2136_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H (2025) Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol 22:26\u201345. https:\/\/doi.org\/10.1038\/s41585-024-00900-z","journal-title":"Nat Rev Urol"},{"key":"2136_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno P, Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS (2019) Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol 76:469\u2013478. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030","journal-title":"Eur Urol"},{"key":"2136_CR21","doi-asserted-by":"publisher","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","volume":"57","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U (2016) The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med 57:79S\u201389S. https:\/\/doi.org\/10.2967\/jnumed.115.170720","journal-title":"J Nucl Med"},{"key":"2136_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","volume":"85","author":"M Corpetti","year":"2024","unstructured":"Corpetti M, M\u00fcller C, Beltran H, de Bono J, Theurillat J-P (2024) Prostate-specific membrane antigen\u2013targeted therapies for prostate cancer: towards improving therapeutic outcomes. Eur Urol 85:193\u2013204. https:\/\/doi.org\/10.1016\/j.eururo.2023.11.018","journal-title":"Eur Urol"},{"key":"2136_CR23","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.Ccr-19-1485","volume":"26","author":"K Current","year":"2020","unstructured":"Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K (2020) Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intratumoral PSMA heterogeneity, clin. Cancer Res 26:2946\u20132955. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1485","journal-title":"Cancer Res"},{"key":"2136_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2967\/jnumed.120.256263","volume":"62","author":"AD Stuparu","year":"2021","unstructured":"Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, L\u00fcckerath K, Slavik R (2021) Mechanisms of resistance to prostate-specific membrane antigen\u2013targeted radioligand therapy in a mouse model of prostate cancer. J Nucl Med 62:989\u2013995. https:\/\/doi.org\/10.2967\/jnumed.120.256263","journal-title":"J Nucl Med"},{"key":"2136_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.119.234559","volume":"61","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Giesel FL, Heussel C-P, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A (2020) Patients resistant against PSMA-targeting \u03b1-radiation therapy often harbor mutations in DNA damage-repair\u2013associated genes. J Nucl Med 61:683\u2013688. https:\/\/doi.org\/10.2967\/jnumed.119.234559","journal-title":"J Nucl Med"},{"key":"2136_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","volume":"71","author":"J Mateo","year":"2017","unstructured":"Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS (2017) DNA repair in prostate cancer: biology and clinical implications. Eur Urol 71:417\u2013425. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.037","journal-title":"Eur Urol"},{"key":"2136_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19:589\u2013608. https:\/\/doi.org\/10.1038\/s41573-020-0073-9","journal-title":"Nat Rev Drug Discov"},{"key":"2136_CR28","doi-asserted-by":"publisher","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","volume":"4","author":"ST Durant","year":"2018","unstructured":"Durant ST, Zheng L, Wang Y, Chen K, Zhang L, Zhang T, Yang Z, Riches L, Trinidad AG, Fok JHL, Hunt T, Pike KG, Wilson J, Smith A, Colclough N, Reddy VP, Sykes A, Janefeldt A, Johnstr\u00f6m P, Varn\u00e4s K, Takano A, Ling S, Orme J, Stott J, Roberts C, Barrett I, Jones G, Roudier M, Pierce A, Allen J, Kahn J, Sule A, Karlin J, Cronin A, Chapman M, Valerie K, Illingworth R, Pass M (2018) The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci Adv 4:eaat1719. https:\/\/doi.org\/10.1126\/sciadv.aat1719","journal-title":"Sci Adv"},{"key":"2136_CR29","doi-asserted-by":"publisher","first-page":"216507","DOI":"10.1016\/j.canlet.2023.216507","volume":"582","author":"G Chen","year":"2024","unstructured":"Chen G, Zheng D, Zhou Y, Du S, Zeng Z (2024) Olaparib enhances radiation-induced systemic anti-tumor effects via activating STING-chemokine signaling in hepatocellular carcinoma. Cancer Lett 582:216507. https:\/\/doi.org\/10.1016\/j.canlet.2023.216507","journal-title":"Cancer Lett"},{"key":"2136_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","volume":"5","author":"R-X Huang","year":"2020","unstructured":"Huang R-X, Zhou P-K (2020) DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther 5:60. https:\/\/doi.org\/10.1038\/s41392-020-0150-x","journal-title":"Signal Transduct Target Ther"},{"key":"2136_CR31","doi-asserted-by":"publisher","first-page":"2304609","DOI":"10.1002\/advs.202304609","volume":"11","author":"J Ji","year":"2024","unstructured":"Ji J, Ding K, Cheng B, Zhang X, Luo T, Huang B, Yu H, Chen Y, Xu X, Lin H, Zhou J, Wang T, Jin M, Liu A, Yan D, Liu F, Wang C, Chen J, Yan F, Wang L, Zhang J, Yan S, Wang J, Li X, Chen G (2024) Radiotherapy-induced astrocyte senescence promotes an immunosuppressive microenvironment in glioblastoma to facilitate tumor regrowth. Adv Sci (Weinh) 11:2304609. https:\/\/doi.org\/10.1002\/advs.202304609","journal-title":"Adv Sci (Weinh)"},{"key":"2136_CR32","doi-asserted-by":"publisher","first-page":"e1490853","DOI":"10.1080\/2162402X.2018.1490853","volume":"7","author":"P Jayaraman","year":"2018","unstructured":"Jayaraman P, Parikh F, Newton JM, Hanoteau A, Rivas C, Krupar R, Rajapakshe K, Pathak R, Kanthaswamy K, MacLaren C, Huang S, Coarfa C, Spanos C, Edwards DP, Parihar R, Sikora AG (2018) TGF-\u03b21 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. Oncoimmunology 7:e1490853. https:\/\/doi.org\/10.1080\/2162402X.2018.1490853","journal-title":"Oncoimmunology"},{"key":"2136_CR33","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman DJ, Akkari L (2023) Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186:1627\u20131651. https:\/\/doi.org\/10.1016\/j.cell.2023.02.020","journal-title":"Cell"},{"key":"2136_CR34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J (2021) Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 18:773\u2013791. https:\/\/doi.org\/10.1038\/s41571-021-00532-x","journal-title":"Nat Rev Clin Oncol"},{"key":"2136_CR35","doi-asserted-by":"publisher","first-page":"107391","DOI":"10.1016\/j.pharmthera.2019.07.002","volume":"203","author":"MH Jin","year":"2019","unstructured":"Jin MH, Oh D-Y (2019) ATM in DNA repair in cancer. Pharmacol Ther 203:107391. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.07.002","journal-title":"Pharmacol Ther"},{"key":"2136_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2016","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, Piulats JM, Gonzalez Mella P, Ng SS, Jaeger D, Parnis FX, Franke FA, Puente J, Carvajal R, Sengel\u00f8v L, McHenry MB, Varma A, van den Eertwegh AJ, Gerritsen W (2016) Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol 35:40\u201347. https:\/\/doi.org\/10.1200\/JCO.2016.69.1584","journal-title":"J Clin Oncol"},{"key":"2136_CR37","doi-asserted-by":"publisher","first-page":"e005060","DOI":"10.1136\/jitc-2022-005060","volume":"10","author":"HK Potluri","year":"2022","unstructured":"Potluri HK, Ferreira CA, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle JW, Kwon O, Marsh IR, Bednarz BP, Hernandez R, Weichert JP, McNeel DG (2022) Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 Blockade is limited by regulatory T cells in murine prostate tumors. J Immunother Cancer 10:e005060. https:\/\/doi.org\/10.1136\/jitc-2022-005060","journal-title":"J Immunother Cancer"},{"key":"2136_CR38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/2326-6066.CIR-17-0134","volume":"6","author":"N-P Rudqvist","year":"2018","unstructured":"Rudqvist N-P, Pilones KA, Lhuillier C, Wennerberg E, Sidhom J-W, Emerson RO, Robins HS, Schneck J, Formenti SC (2018) Demaria, radiotherapy and CTLA-4 Blockade shape the TCR repertoire of tumor-infiltrating T cells. Cancer Immunol Res 6:139\u2013150. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0134","journal-title":"Cancer Immunol Res"},{"key":"2136_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","volume":"57","author":"A Franken","year":"2024","unstructured":"Franken A, Bila M, Mechels A, Kint S, Van Dessel J, Pomella V, Vanuytven S, Philips G, Bricard O, Xiong J, Boeckx B, Hatse S, Van Brussel T, Schepers R, Van Aerde C, Geurs S, Vandecaveye V, Hauben E, Vander Poorten V, Verbandt S, Vandereyken K, Qian J, Tejpar S, Voet T, Clement PM (2024) Lambrechts, CD4\u2009+\u2009T cell activation distinguishes response to anti-PD-L1\u2009+\u2009anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity 57:541\u2013558e547. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.007","journal-title":"Immunity"},{"key":"2136_CR40","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","volume":"184","author":"F Marangoni","year":"2021","unstructured":"Marangoni F, Zhakyp A, Corsini M, Geels SN, Carrizosa E, Thelen M, Mani V, Pr\u00fc\u00dfmann JN, Warner RD, Ozga AJ, Di Pilato M, Othy S, Mempel TR (2021) Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell 184:3998\u20134015e3919. https:\/\/doi.org\/10.1016\/j.cell.2021.05.027","journal-title":"Cell"},{"key":"2136_CR41","doi-asserted-by":"publisher","first-page":"15760","DOI":"10.1038\/ncomms15760","volume":"8","author":"F Natale","year":"2017","unstructured":"Natale F, Rapp A, Yu W, Maiser A, Harz H, Scholl A, Grulich S, Anton T, H\u00f6rl D, Chen W, Durante M, Taucher-Scholz G, Leonhardt H, Cardoso MC (2017) Identification of the elementary structural units of the DNA damage response. Nat Commun 8:15760. https:\/\/doi.org\/10.1038\/ncomms15760","journal-title":"Nat Commun"},{"key":"2136_CR42","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA (2023) Antigen presentation in cancer \u2014 mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol 20:604\u2013623. https:\/\/doi.org\/10.1038\/s41571-023-00789-4","journal-title":"Nat Rev Clin Oncol"},{"key":"2136_CR43","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N, Melief CJM, Kastenm\u00fcller W (2018) CD4\u2009+\u2009T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18:635\u2013647. https:\/\/doi.org\/10.1038\/s41577-018-0044-0","journal-title":"Nat Rev Immunol"},{"key":"2136_CR44","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1007\/s00259-024-06844-1","volume":"51","author":"H Rauch","year":"2024","unstructured":"Rauch H, Kitzberger C, Janghu K, Hawarihewa P, Nguyen NT, Min Y, Ballke S, Steiger K, Weber WA, Kossatz S (2024) Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. Eur J Nucl Med Mol Imaging 51:4099\u20134110. https:\/\/doi.org\/10.1007\/s00259-024-06844-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2136_CR45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268902","author":"A Hallqvist","year":"2025","unstructured":"Hallqvist A, Brynjarsd\u00f3ttir E, Krantz T, Sj\u00f6gren M, Svensson J, Bernhardt P (2025) 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.124.268902","journal-title":"J Nucl Med"},{"key":"2136_CR46","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, Banks PD, Wallace R, Hamid A, Inderjeeth AJ, Tran B, Azad A, Alipour R, Kong G, Ravi Kumar A, Saghebi J, Williams S, Akhurst TJ, Hicks RJ, Hofman MS (2023) LuPARP: phase 1 trial of 177Lu-PSMA-617 and Olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 41:5005\u20135005. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5005","journal-title":"J Clin Oncol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-025-02136-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-025-02136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T19:03:05Z","timestamp":1758913385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-025-02136-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":46,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2136"],"URL":"https:\/\/doi.org\/10.1007\/s10495-025-02136-7","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,26]]},"assertion":[{"value":"9 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}